Mizuho Wants "to Get More Constructive" on Valeant Pharma (VRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall St inches lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil slides on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
- Ovintiv adds 41,000 acres in Permian and Montney deals
Valeant Pharma (VRX) AdCom on Brodalumab Begins
July 19, 2016 8:10 AM EDTValeant Pharma (NYSE: VRX) FDA advisory committee meeting for Brodalumab is starting now. Click here to access the webcast.
For the Brodalumab briefing docs, click here.
Shares of Valeant are lower in early trading Tuesday.
... MoreValeant (VRX) Scripts Plunge Amid 4-Day Week
July 18, 2016 10:16 AM EDTRBC Capital analyst Douglas Miehm notes Valeant Pharmaceuticals (NYSE: VRX) scripts fell following a four-day week (July 4th): Derm NRx were down 29.4% WoW and ophth NRx were down 19.1%.
NRx Derm products down 29.4% WoW. For the week ending July 8th, new derm scripts (NRx) were down 29.4% vs. up 0.9% the prior week due to a four-day week... More
